The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2024 | CAPRI 2-GOIM: advancing precision therapy for RAS/BRAF wild type tumors
Giulia Martini, MD, PhD, Università degli Studi della Campania Luigi Vanvitelli, Naples, Italy, reflects on the findings from the CAPRI 2-GOIM trial (NCT05312398) investigating cetuximab-based therapies. The results are significant for patients with RAS/BRAF wild type tumors in metastatic colorectal cancer (mCRC), as molecular profiling showed which patients can benefit more from anti-EGFR therapy. The next step will be to correlate these findings with the survival findings that will evolve from the CAPRI 2-GOIM trial in the near future. This interview took place at 2024 European Society for Medical Oncology (ESMO) Gastrointestinal Cancer Annual Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
